Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexlansoprazole regarding nocturnal acid breakthrough in healthy subjects. Methods: In a randomized, open-label, single-dose, balanced incomplete block crossover study, 24 healthy male volunteers were enrolled and randomized to receive oral tegoprazan (50, 100, or 200 mg) or dexlansoprazole (60 mg) during each of two administration periods, separated by a 7- to 10-day washout period. Blood samples were collected for pharmacokinetic parameter analysis; gastric monitoring was performed for pharmacodynamic parameter evaluation. Results: All 24 subjects completed the study. Average maximum plasma concentration, area under the plasma concentration–time curve, and mean time with gastric pH >4 and pH >6 for tegoprazan demonstrated dose-dependent incremental increases. All the tegoprazan groups reached mean pH ≥4 within 2 hours, whereas the dexlansoprazole group required 7 hours after drug administration. Based on pharmacodynamic parameters up to 12 hours after evening dosing, 50, 100, and 200 mg of tegoprazan presented a stronger acid-suppressive effect than 60 mg of dexlansoprazole. Moreover, the dexlansoprazole group presented a comparable acid-suppressive effect with the tegoprazan groups 12 hours after dosing. Conclusions: All the tegoprazan groups demonstrated a significantly faster onset of gastric pH increase and longer holding times above pH >4 and pH >6 up to 12 hours after evening dosing than the dexlansoprazole group.
Abstract
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexlansoprazole regarding nocturnal acid breakthrough in healthy subjects. Methods: In a randomized, open-label, single-dose, balanced incomplete block crossover study, 24 healthy male volunteers were enrolled and randomized to receive oral tegoprazan (50, 100, or 200 mg) or dexlansoprazole (60 mg) during each of two administration periods, separated by a 7- to 10-day washout period. Blood samples were collected for pharmacokinetic parameter analysis; gastric monitoring was performed for pharmacodynamic parameter evaluation. Results: All 24 subjects completed the study. Average maximum plasma concentration, area under the plasma concentration–time curve, and mean time with gastric pH >4 and pH >6 for tegoprazan demonstrated dose-dependent incremental increases. All the tegoprazan groups reached mean pH ≥4 within 2 hours, whereas the dexlansoprazole group required 7 hours after drug administration. Based on pharmacodynamic parameters up to 12 hours after evening dosing, 50, 100, and 200 mg of tegoprazan presented a stronger acid-suppressive effect than 60 mg of dexlansoprazole. Moreover, the dexlansoprazole group presented a comparable acid-suppressive effect with the tegoprazan groups 12 hours after dosing. Conclusions: All the tegoprazan groups demonstrated a significantly faster onset of gastric pH increase and longer holding times above pH >4 and pH >6 up to 12 hours after evening dosing than the dexlansoprazole group.
참고문헌 (25)
- Gold BD, "Dexlansoprazole for heartburn relief in adolescents with symptomatic, nonerosive gastro-esophageal reflux disease", Dig Dis Sci, 62, pp.3059~3068 (2017)
- Pilotto A, "Recent advances in the treatment of GERD in the elderly : focus on proton pump inhibitors", Int J Clin Pract, 59, pp.1204~1209 (2005)
- Tytgat GN, "Are there unmet needs in acid suppression", Best Pract Res Clin Gastroenterol, 18(Suppl), pp.67~72 (2004)
- Peghini PL, "Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors", Am J Gastroenterol, 93, pp.763~767 (1998)
- Pehlivanov ND, "Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease : a double-blind, cross-over study", Aliment Pharmacol Ther, 18, pp.883~890 (2003)
- Xue S, "Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors", Aliment Pharmacol Ther, 15, pp.1351~1356 (2001)
- Fackler WK, "Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough", Gastroenterology, 122, pp.625~632 (2002)
- Tadayuki Oshima, "Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases", Journal of Neurogastroenterology and Motility (JNM), 24(3), pp.334~344 (2018), 대한소화기 기능성질환∙운동학회[DOI]
- Takahashi N, "Tegoprazan, a novel potassiumcompetitive acid blocker to control gastric acid secretion and motility", J Pharmacol Exp Ther, 364, pp.275~286 (2018)
- Han S, "Randomised clinical trial : safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan(CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects", Aliment Pharmacol Ther, 50, pp.751~759 (2019)
- Lee KJ, "Randomised phase 3 trial : tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis", Aliment Pharmacol Ther, 49, pp.864~872 (2019)
- Scarpignato C, "Editorial : towards extended acid suppression : the search continues", Aliment Pharmacol Ther, 42, pp.1027~1029 (2015)
- Hunt R, "Acid suppression for reflux disease : "off-thepeg"or a tailored approach?", Clin Gastroenterol Hepatol, 10, pp.210~213 (2012)
- Skrzydło-Radomańska B, "Dexlansoprazole : a new-generation proton pump inhibitor", Prz Gastroenterol, 10, pp.191~196 (2015)
- Han S, "Pharmacokinetics, pharmacodynamics and food-effect of single oral dose of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker (PCAB)in healthy male subjects", 2017 Korea Digestive Disease Week (2017)
- Wallace JL, "New pharmacologic therapies in gastrointestinal disease", Gastroenterol Clin North Am, 39, pp.709~720 (2010)
- Kukulka M, "Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg", Clin Exp Gastroenterol, 4, pp.213~220 (2011)
- Weigt J, "Nocturnal gastric acid breakthrough is not associated with nighttime gastroesophageal reflux in GERD patients", Dig Dis, 27, pp.68~73 (2009)
- Farup C, "The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life", Arch Intern Med, 161, pp.45~52 (2001)
- Shaker R, "Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function : the results of a Gallup survey conducted on behalf of the American Gastroenterological Association", Am J Gastroenterol, 98, pp.1487~1493 (2003)
- Howden CW, "Clinical trial : efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis : maintenance of healing and symptom relief", Aliment Pharmacol Ther, 30, pp.895~907 (2009)
- Kukulka M, "Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole", Therap Adv Gastroenterol, 9, pp.759~769 (2016)
- Lee RD, "The effect of timeof-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR : evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor", Aliment Pharmacol Ther, 31, pp.1001~1011 (2010)
- Yang E, "Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole", Br J Clin Pharmacol, 88, pp.3288~3296 (2022)
- 황준기, "Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects", Translational and Clinical Pharmacology, 27(2), pp.80~85 (2019), 대한임상약리학회